Savolitinib Clinical Trials

4 actively recruiting trials across 1 location

Also known as: AZD6094, AZD6094, HMPL-504, volitinib, ORPATHYS

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

The First Affiliated Hospital of Guangzhou Medical University1
Sun Yat-sen University1
Jeeyun Lee1
AstraZeneca1

Indications

Cancer4
Lung Cancer3
Non-Small-Cell Lung1
Stomach Cancer, Adenocarcinoma1
Mutation1

Other3 trials

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Phase 2

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Phase 1/2

La Jolla, California1 trial

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.